Cipemastat (Ro 32-3555) is a potent and selective inhibitor of human collagenases 1, 2, and 3, with potential therapeutic applications in diseases involving excessive extracellular matrix degradation, such as rheumatoid arthritis and osteoarthritis; it inhibits IL-1α-induced cartilage degradation in vitro in a concentration-dependent manner (IC50 = 60 nM) without cytotoxic effects on chondrocytes; in vivo, it significantly reduces cartilage destruction in animal models of arthritis, as evidenced by increased hydroxyproline content and preserved cartilage area in Cipemastat-treated animals compared to vehicle controls.